Home Stock

Stock Research: Roche

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Roche

VTX:ROG CH0012032048
9
  • Value
    62
  • Growth
    31
  • Safety
    Safety
    32
  • Combined
    20
  • Sentiment
    21
  • 360° View
    360° View
    9
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Roche Holding AG is a healthcare company focused on pharmaceuticals and diagnostics. The company operates in the pharmaceuticals and diagnostics industries with business segments in Pharmaceuticals (Roche Pharmaceuticals and Chugai) and Diagnostics (Diabetes Care, Molecular Diagnostics, Professional Diagnostics, and Tissue Diagnostics). The company develops medicines for oncology, immunology, infectious diseases, ophthalmology, and neuroscience. In the last fiscal year, the company had a market cap of $258,542 million, profits of $49,371 million, and revenue of $66,683 million, with 103249 employees.

more

ANALYSIS: With an Obermatt 360° View of 9 (better than 9% compared with alternatives), overall professional sentiment and financial characteristics for the stock Roche are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Roche. Only the consolidated Value Rank has an attractive rank of 62, which means that the share price of Roche is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 62% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 31, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 32, meaning the company has a riskier financing structure than 68% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 79% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 21. ...read more

more
Strongest Rank Analyst Opinions
Weakest Rank Opinions Change
Country Switzerland
Industry Pharmaceuticals
Size XX-Large
Website roche.com
Index
SPI
SPI
SMI
Roche stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
62 51 61 50
Growth
31 55 17 31
Safety
Safety
32 14 30 45
Sentiment
21 79 64 14
360° View
360° View
9 45 30 24
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
7 24 26 55
Opinions Change
100 75 54 16
Pro Holdings
n/a 92 63 30
Market Pulse
25 67 79 39
Sentiment
21 79 64 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
62 51 61 50
Growth
31 55 17 31
Safety Safety
32 14 30 45
Combined
20 22 14 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
56 31 39 36
Price vs. Earnings (P/E)
42 56 70 58
Price vs. Book (P/B)
23 10 12 10
Dividend Yield
85 87 90 86
Value
62 51 61 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
24 34 25 12
Profit Growth
100 51 29 37
Capital Growth
26 51 46 39
Stock Returns
29 80 36 76
Growth
31 55 17 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
16 12 20 43
Refinancing
40 22 21 14
Liquidity
61 63 73 74
Safety Safety
32 14 30 45

Similar Stocks

Discover high‑ranked alternatives to Roche and broaden your portfolio horizons.

Swatch

VTX:UHR
Country: Switzerland
Industry: Apparel, Accessories, Luxury
Size: X-Large
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Faes Farma

MCE:FAE
Country: Spain
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Alcon

VTX:ALC
Country: Switzerland
Industry: Health Care Supplies
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The only strength is good value. All other factors (growth, safety, and sentiment) are below average. This stock is highly sensitive to a crisis and is not advisable. Avoid unless you have solid, independent reasons to believe a significant turnaround is imminent.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews